Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study-Reference-Cited by-同舟云学术

Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study

Published:2022-07 Issue:1 Volume:166 Page:36-43
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

O'Cearbhaill Roisin E.,Pérez-Fidalgo Jose-Alejandro,Monk Bradley J.,Tusquets Ignacio,McCormick Colleen,Fuentes Jose,Moore Richard G.,Vulsteke Christof,Shahin Mark S.,Forget Frédéric,Bradley William H.,Hietanen Sakari,O'Malley David M.,Dørum Anne,Slomovitz Brian M.,Baumann Klaus,Selle Frédéric,Calvert Paula M.,Artioli Grazia,Levy Tally,Kumar Aalok,Malinowska Izabela A.,Li Yong,Gupta Divya,González-Martín Antonio

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference16 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J. Clin.,2021

2. SEER cancer Statistics Review;Howlader,2020

3. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Ledermann;Ann. Oncol.,2013

4. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline;Wright;J. Clin. Oncol.,2016

5. First-line treatment of women with advanced ovarian cancer: focus on bevacizumab;Marchetti;Onco. Targets Ther.,2019

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of molecular testing on the surgical management of advanced epithelial ovarian cancer;Critical Reviews in Oncology/Hematology;2024-10

2. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from PRIMA/ENGOT-OV26/GOG-3012 trial;Annals of Oncology;2024-09

3. Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study;International Journal of Gynecologic Cancer;2024-07

4. Updates in the Use of Targeted Therapies for Gynecologic Cancers;American Society of Clinical Oncology Educational Book;2024-06

5. PARP inhibitor maintenance treatment for newly diagnosed ovarian cancer patients: a real-world study from China;Frontiers in Oncology;2024-02-02